References
- Institute for Quality and Efficiency in Health Care. Ticagrelor – Benefit Assessment According to § 35a Social Code Book V (in German). Institute for Quality and Efficiency in Health Care, Cologne, Germany (2011).
- Wallentin L, Becker RC, Budaj A et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009).
- Institute for Quality and Efficiency in Health Care. General Methods for the Assessment of the Relation of Benefits to Costs - Version 1.0 (in German). Institute for Quality and Efficiency in Health Care, Cologne, Germany (2009).
- Gandjour A. Germany's decision rule for cost-effectiveness analysis on drugs: a comparative analysis with other decision rules. Appl. Health Econ. Health Policy 9(2), 65–71 (2011).
- Gandjour A. Presenting Germany's drug pricing rule as a cost-per-QALY rule. Health Care Manag. Sci. 15(2), 103–107 (2012).
- Gandjour A, Gafni A. The German method for setting ceiling prices for drugs: in some cases less data are required. Expert Rev. Pharmacoecon. Outcomes Res. 11(4), 403–409 (2011).
- Gandjour A. Reference pricing and price negotiations for innovative new drugs: viable policies in the long term? Pharmacoeconomics 31(1), 11–14 (2013).
- Institute for Quality and Efficiency in Health Care. Clopidogrel Plus Acetylsalicylic Acid in Acute Coronary Syndrome (in German). Institute for Quality and Efficiency in Health Care, Cologne, Germany (2009).
- Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494–502 (2001).
- Serebruany VL. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thromb. Haemost. 105(5), 752–759 (2011).
- Tsevat J, Goldman L, Soukup JR et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med. Decis. Making 13(2), 161–165 (1993).
- Günther K. Identifikation von Risikogruppen für myokardinfarktbedingte Letalität und nicht-Leitliniengerechte Versorgung unter Patienten mit Nicht-ST-Streckenhebungs-Myokardinfarkt (NSTEMI) oder ST-Streckenhebungs-Myokardinfarkt (STEMI) in Bremen. University of Bremen, Bremen, Germany (2010).
- Birch S, Gafni A. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? J. Health Econ. 11(3), 279–296 (1992).
- Birch S, Gafni A. Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems. J. Health Econ. 12(4), 469–476 (1993).
- Weinstein MC, Zeckhauser R. Critical ratios and efficient allocation. J. Public Econ. 2, 147–157 (1973).
- Schlander M, Jaecker A, Voelkl M. Arzneimittelpreise: Preisbildung in einem besonderen Markt. Dtsch Ärztebl. 109(11), A524–A528 (2012).
- Schlander M, Jaecker A, Voelkl M. Arzneimittelpreisregulierung nach den Prinzipien der Sozialen Marktwirtschaft. PharmInd. 75(3), 384–389 (2013).
- Cost-Effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, NY, USA (1996).
Website
- Cost-effectiveness analysis registry. www.cearegistry.org